Indivior (NASDAQ:INDV) Sees Strong Trading Volume – Should You Buy?

Shares of Indivior PLC (NASDAQ:INDV) saw unusually-high trading volume on Friday . Approximately 419,314 shares were traded during trading, an increase of 6% from the previous session’s volume of 396,994 shares.The stock last traded at $7.58 and had previously closed at $7.98.

Wall Street Analysts Forecast Growth

INDV has been the topic of a number of recent research reports. Piper Sandler reissued an “overweight” rating and set a $15.00 price target (down previously from $22.00) on shares of Indivior in a research report on Friday. Craig Hallum dropped their price target on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday.

Indivior Stock Performance

The business has a 50-day moving average of $10.99 and a two-hundred day moving average of $14.71. The company has a market cap of $1.03 billion, a P/E ratio of 746.00 and a beta of 0.68. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The company had revenue of $299.00 million for the quarter, compared to the consensus estimate of $285.90 million. On average, sell-side analysts predict that Indivior PLC will post 1.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in Indivior in the second quarter valued at about $188,000. VELA Investment Management LLC purchased a new stake in Indivior in the second quarter valued at about $235,000. XTX Topco Ltd purchased a new stake in Indivior in the second quarter valued at about $249,000. Cubist Systematic Strategies LLC raised its stake in Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after buying an additional 6,121 shares during the last quarter. Finally, Cannon Global Investment Management LLC purchased a new stake in Indivior in the first quarter valued at about $563,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.